Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature

Overview

Journal Case Rep Neurol

Publisher Karger

Specialty Neurology

Date 2018 Oct 17

PMID 30323758

Citations 6

Authors

Sakis Lambrianides

Evgenios Kinnis

Eleni Leonidou

Marios Pantzaris

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a relatively common immune-mediated chronic inflammatory skin disease. It is well known that interferon-beta, a drug used in the management of relapsing-remitting multiple sclerosis, could exacerbate or induce de novo psoriasis. There is limited evidence in the literature based only on case reports that natalizumab could induce or aggravate psoriasis. In this case study, we present a 33-year-old patient who developed plaque psoriasis during natalizumab treatment.

Citing Articles

Multiple Sclerosis and Autoimmune Comorbidities.

Nociti V, Romozzi M J Pers Med. 2022; 12(11).

PMID: 36579555 PMC: 9698878. DOI: 10.3390/jpm12111828.

Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review.

Sirbu C, Ivan R, Vasile T, Eftimie L, Costache D J Clin Med. 2022; 11(13).

PMID: 35806991 PMC: 9267819. DOI: 10.3390/jcm11133702.

Natalizumab-Induced Pustular Psoriasis of Palms and Soles.

Ozarslan B, Russo T, Argenziano G, Piccolo V Dermatol Pract Concept. 2022; 12(2):e2022088.

PMID: 35646438 PMC: 9116523. DOI: 10.5826/dpc.1202a88.

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.

Brummer T, Ruck T, Meuth S, Zipp F, Bittner S Ther Adv Neurol Disord. 2021; 14:17562864211035542.

PMID: 34457039 PMC: 8388232. DOI: 10.1177/17562864211035542.

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab.

Berkovich R, Yakupova A, Eskenazi J, Carlson N, Steinman L Neurol Neuroimmunol Neuroinflamm. 2021; 8(2).

PMID: 33589543 PMC: 8057059. DOI: 10.1212/NXI.0000000000000961.

References

Bezabeh S, Flowers C, Kortepeter C, Avigan M . Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010; 31(9):1028-35. DOI: 10.1111/j.1365-2036.2010.04262.x. View

Buzzard K, Broadley S, Butzkueven H . What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?. Int J Mol Sci. 2012; 13(10):12665-709. PMC: 3497294. DOI: 10.3390/ijms131012665. View

Hutchinson M . Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2008; 3(2):259-68. PMC: 1936307. DOI: 10.2147/tcrm.2007.3.2.259. View

Axtell R, Raman C, Steinman L . Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011; 32(6):272-7. PMC: 5414634. DOI: 10.1016/j.it.2011.03.008. View

Frieder J, Kivelevitch D, Menter A . Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018; 9(1):5-21. PMC: 5761942. DOI: 10.1177/2040622317738910. View

Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O . Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011; 208(11):2291-303. PMC: 3201195. DOI: 10.1084/jem.20100977. View

Havrdova E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E . Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016; 263(7):1287-95. DOI: 10.1007/s00415-016-8128-x. View

Deng Y, Chang C, Lu Q . The Inflammatory Response in Psoriasis: a Comprehensive Review. Clin Rev Allergy Immunol. 2016; 50(3):377-89. DOI: 10.1007/s12016-016-8535-x. View

Mitroulis I, Alexaki V, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T . Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 2014; 147:123-135. PMC: 4324083. DOI: 10.1016/j.pharmthera.2014.11.008. View

10.

Egeberg A, Mallbris L, Gislason G, Skov L, Hansen P . Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study. J Invest Dermatol. 2016; 136(1):93-8. DOI: 10.1038/JID.2015.350. View

11.

Marrie R, Patten S, Tremlett H, Wolfson C, Leung S, Fisk J . Increased incidence and prevalence of psoriasis in multiple sclerosis. Mult Scler Relat Disord. 2017; 13:81-86. DOI: 10.1016/j.msard.2017.02.012. View

12.

Kwok T, Loo W, Guenther L . Psoriasis and multiple sclerosis: is there a link?. J Cutan Med Surg. 2010; 14(4):151-5. DOI: 10.2310/7750.2010.09063. View

13.

Polman C, OConnor P, Havrdova E, Hutchinson M, Kappos L, Miller D . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):899-910. DOI: 10.1056/NEJMoa044397. View

14.

Buhler U, Fleischer V, Luessi F, Rezk A, Belikan P, Graetz C . Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment. Mult Scler. 2016; 23(4):567-576. DOI: 10.1177/1352458516658559. View

15.

Marrie R, Reider N, Cohen J, Stuve O, Sorensen P, Cutter G . A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2014; 21(3):282-93. PMC: 4429166. DOI: 10.1177/1352458514564490. View

16.

Millan-Pascual J, Turpin-Fenoll L, del Saz-Saucedo P, Rueda-Medina I, Navarro-Munoz S . Psoriasis during natalizumab treatment for multiple sclerosis. J Neurol. 2012; 259(12):2758-60. DOI: 10.1007/s00415-012-6713-1. View

17.

Mills E, Ogrodnik M, Plave A, Mao-Draayer Y . Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Front Neurol. 2018; 9:5. PMC: 5787128. DOI: 10.3389/fneur.2018.00005. View

18.

La Mantia L, Capsoni F . Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci. 2009; 31(3):337-9. DOI: 10.1007/s10072-009-0184-x. View

19.

Vacchiano V, Foschi M, Sabattini L, Scandellari C, Lugaresi A . Arthritic psoriasis during natalizumab treatment: a case report and review of the literature. Neurol Sci. 2017; 39(1):181-183. DOI: 10.1007/s10072-017-3112-5. View